 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
17 News |  |
- | veldoreotide (DG3173) / Strongbridge
Journal: Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. (Pubmed Central) - Oct 25, 2021
In the BON-1 cells expressing SSTR4, veldoreotide inhibited cell proliferation more than somatostatin SS-14 (71.2% vs. 79.7%) and to a similar extent as the SSTR4 agonist J-2156 in the presence of SSTR2 and SSTR5 antagonists. Veldoreotide is a full agonist of SSTR2, SSTR4, and SSTR5.
- veldoreotide (DG3173) / Strongbridge
[VIRTUAL] Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1319;
In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors.
- veldoreotide (DG3173) / Strongbridge
Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1796;
In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors.
- | veldoreotide (DG3173) / Xeris Biopharma
New P1 trial: Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer (clinicaltrials.gov) - Oct 31, 2019
P1, N=30, Recruiting, Sponsor: Al-Azhar University
- veldoreotide (DG3173) / Xeris Biopharma
Trial completion, Enrollment change, Trial primary completion date: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (clinicaltrials.gov) - Feb 15, 2018
P2, N=8, Completed, Sponsor: Aspireo Pharmaceuticals Limited
Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors. Active, not recruiting --> Completed | N=20 --> 8 | Trial primary completion date: Sep 2015 --> Mar 2014
- veldoreotide (DG3173) / Xeris Biopharma
Trial primary completion date: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (clinicaltrials.gov) - Feb 6, 2015
P2, N=20, Active, not recruiting, Sponsor: Aspireo Pharmaceuticals Limited
Active, not recruiting --> Completed | N=20 --> 8 | Trial primary completion date: Sep 2015 --> Mar 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- veldoreotide (DG3173) / Xeris Biopharma
New P2 trial: Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. (clinicaltrials.gov) - Sep 10, 2014
P2, N=20, Completed, Sponsor: Aspireo Pharmaceuticals Limited
- veldoreotide (DG3173) / Xeris Biopharma
New P2 trial: The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (clinicaltrials.gov) - Aug 15, 2014
P2, N=20, Active, not recruiting, Sponsor: Aspireo Pharmaceuticals Limited
- veldoreotide (DG3173) / Xeris Biopharma
New P1 trial: Single Ascending Dose Tolerability Study of DG3173 (clinicaltrials.gov) - Aug 15, 2014
P1, N=72, Completed, Sponsor: Aspireo Pharmaceuticals Limited
- veldoreotide (DG3173) / Xeris Biopharma
New P1 trial: Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173 (clinicaltrials.gov) - Aug 15, 2014
P1, N=42, Completed, Sponsor: Aspireo Pharmaceuticals Limited
- veldoreotide (DG3173) / Xeris Biopharma
New P1 trial: Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173 (clinicaltrials.gov) - Aug 15, 2014
P1, N=8, Completed, Sponsor: Aspireo Pharmaceuticals Limited